LIOTTA, MARTA
LIOTTA, MARTA
Dipartimento di Medicina Clinica e Sperimentale
ASMA ALLERGICO SEVERO IN TRATTAMENTO CON OMALIZUMAB: RISULTATI IN TERMINI DI QUALITA’ DI VITA
2017-01-01 Liotta, Marta; Papia, Francesco; Cicero, Francesca; Saitta, Salvatore; Gangemi, S.; Ricciardi, Luisa
Clinical Psychology and Clinical Immunology: is there a link between Alexithymia and severe Asthma?
2023-01-01 Ricciardi, L.; Spatari, G.; Vicario, C. M.; Liotta, M.; Cazzato, V.; Gangemi, S.; Martino, G.
Dupilumab‐Associated, Long-Lasting, Late-Onset, Large Local Reaction at the Injection Site in a Patient Treated for T2 Severe Asthma: A Case Report
2023-01-01 Maria Cutroneo, Paola; Gammeri, Luca; Liotta, Marta; Spina, Edoardo; Ricciardi, Luisa
Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
2022-01-01 Ricciardi, Luisa; Papia, Francesco; Liotta, Marta; Cicero, Francesca; Isola, Stefania; Tartarisco, Gennaro; Furci, Fabiana; Gangemi, Sebastiano
Omalizumab in Severe-Allergic Asthma:the Impact on Real Life Patients
2019-01-01 Ricciardi, Luisa; Liotta, Marta; Papia, Francesco; Isola, Stefania; Saitta, Salvatore
Omalizumab: A useful tool for inducing tolerance to Bee Venom Immunotherapy
2015-01-01 Ricciardi, Luisa; Arena, ELEONORA MARIA; Genovese, Carmelo; Gambino, Marco; Liotta, Marta; Saitta, Salvatore
PPI adverse drugs reactions: a retrospective study
2019-01-01 Casciaro, Marco; Navarra, Michele; Inferrera, Giuseppina; Liotta, Marta; Gangemi, Sebastiano; Minciullo, Paola Lucia
Severe allergic asthma: Does alexithymia interfere with omalizumab treatment outcome?
2021-01-01 Liotta, Marta; Liotta, Marco; Saitta, Salvatore; Ricciardi, Luisa
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ASMA ALLERGICO SEVERO IN TRATTAMENTO CON OMALIZUMAB: RISULTATI IN TERMINI DI QUALITA’ DI VITA | 1-gen-2017 | Liotta, Marta; Papia, Francesco; Cicero, Francesca; Saitta, Salvatore; Gangemi, S.; Ricciardi, Luisa | |
| Clinical Psychology and Clinical Immunology: is there a link between Alexithymia and severe Asthma? | 1-gen-2023 | Ricciardi, L.; Spatari, G.; Vicario, C. M.; Liotta, M.; Cazzato, V.; Gangemi, S.; Martino, G. | |
| Dupilumab‐Associated, Long-Lasting, Late-Onset, Large Local Reaction at the Injection Site in a Patient Treated for T2 Severe Asthma: A Case Report | 1-gen-2023 | Maria Cutroneo, Paola; Gammeri, Luca; Liotta, Marta; Spina, Edoardo; Ricciardi, Luisa | |
| Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap | 1-gen-2022 | Ricciardi, Luisa; Papia, Francesco; Liotta, Marta; Cicero, Francesca; Isola, Stefania; Tartarisco, Gennaro; Furci, Fabiana; Gangemi, Sebastiano | |
| Omalizumab in Severe-Allergic Asthma:the Impact on Real Life Patients | 1-gen-2019 | Ricciardi, Luisa; Liotta, Marta; Papia, Francesco; Isola, Stefania; Saitta, Salvatore | |
| Omalizumab: A useful tool for inducing tolerance to Bee Venom Immunotherapy | 1-gen-2015 | Ricciardi, Luisa; Arena, ELEONORA MARIA; Genovese, Carmelo; Gambino, Marco; Liotta, Marta; Saitta, Salvatore | |
| PPI adverse drugs reactions: a retrospective study | 1-gen-2019 | Casciaro, Marco; Navarra, Michele; Inferrera, Giuseppina; Liotta, Marta; Gangemi, Sebastiano; Minciullo, Paola Lucia | |
| Severe allergic asthma: Does alexithymia interfere with omalizumab treatment outcome? | 1-gen-2021 | Liotta, Marta; Liotta, Marco; Saitta, Salvatore; Ricciardi, Luisa |